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Epidemiological studies have demonstrated that ginseng
intake decreases the risk of cancer. Ginseng saponins (gin-
senosides) have been regarded as principal components
responsible for the majority of pharmacological activities
exerted by ginseng. IH-901 [20-O-b-D-glucopyranosyl-20(S)-
protopanaxadiol], an intestinal bacterial metabolite derived
from protopanaxadiol-type saponins of Panax ginseng
C.A. Meyer, has been reported to possess antitumor effects,
including inhibition of invasion, metastasis and angiogen-
esis and induction of tumor cell apoptosis. Tumor promo-
tion often accompanies an elevated ornithine decarboxylase
(ODC) activity, acute inflammation and induction of
cyclooxygenase-2 (COX-2) activity. Here we examined the
effects of IH-901 on tumor promotion and related molecu-
lar events inmouse skin in vivo.Mouse ear edema induced by
the prototype tumor promoter 12-O-tetradecanoylphorbol-
13-acetate (TPA) was repressed by IH-901 pre-treatment
in a dose-dependent manner. Topical application of IH-901
onto shaven backs of female ICR mice led to the inhibition
of TPA-induced expression of COX-2 and production of
prostaglandin E2. The eukaryotic transcription factor NF-
kB has been involved in intracellular signaling pathways
associated with inflammation and carcinogenesis. IH-901
pre-treatment inhibited TPA-induced epidermal NF-kB
DNA binding in mouse skin, which appeared to be
mediated by blocking phosphorylation and subsequent
degradation of IkBa. In an attempt to elucidate the mole-
cular mechanisms by which IH-901 inactivates NF-kB, its
effects on activation of upstream signaling kinases were
explored. IH-901 also inhibited the activation of ERK1/2
and Akt signaling. When IH-901 was treated topically
prior to TPA, expression and activity of ODC were
inhibited dose-dependently. In addition, IH-901 given
prior to each topical dose of TPA markedly lowered
the number of papillomas in mouse skin induced by 7,
12-dimethylbenz[a]anthracene. Taken together, these
findings suggest that IH-901 exerts anti-inflammatory
effects by inhibiting TPA-induced COX-2 expression,
which may contribute to its antitumor-promoting effects
on mouse skin carcinogenesis.
Introduction
There have been considerable efforts to search for naturally
occurring substances for the intervention of carcinogenesis.
Many components derived from dietary or medicinal plants
have been found to possess substantial chemopreventive prop-
erties. The roots or rhizome of several varieties of Panax plants
(e.g. Panax ginseng, Panax notoginseng, Panax japonicus and
Panax quinquefolium) have been used in traditional oriental
medicine for the treatment of many disorders, such as inflam-
mation and cancer as well as for enhancing physical strength.
Among them, P.ginseng C. A. Meyer is most widely used
in Asia. It has diverse biological and pharmacological effects,
which are mainly attributed to triterpenoid saponin compo-
nents, collectively named ginsenosides (1). A number of sapo-
nins isolated so far from ginseng and its congeners have been
extensively investigated with regard to their possible antitumor
activity.
Recently, several ginseng saponin metabolites formed by
intestinal bacteria were identified after oral administration
of ginseng extracts in humans and rats. For example, ginseno-
side Rh1 is a metabolite of ginsenoside Rg1, but both have
different effects on the production of cytokines in THP-1
cells stimulated by bacterial lipopolysaccharide and 12-O-
tetradecanoylphorbol-13-acetate (TPA) (2). Another well-
defined metabolite of ginsenosides is IH-901 (also known as
M1 or compound K). IH-901 [20-O-b-D-glucopyranosyl-20(S)-
protopanaxadiol] (structure shown in Figure 1) is one of the
metabolites detected in blood after the oral administration of
ginsenoside Rb1, Rb2 or Rc to mice, and is speculated to be
the major form of protopanaxadiol saponins absorbed from
the intestine (3--6). IH-901 was found to be rapidly absorbed
from the gastrointestinal tract after oral administration. On
the other hand, IH-901 appeared late and was retained for a
long period of time in the plasma after oral administration
of ginsenoside-Rb1, which itself is hardly absorbed (7). It
has been revealed that Prevotella oris (8) and Eubacterium
sp. A-44 (7) are major bacterial species capable of hydrolyz-
ing Rb1 to IH-901 as illustrated in Figure 1. IH-901 has been
reported to inhibit glucose uptake by tumor cells and to
reverse the multi-drug resistance in tumor cells (9). It also
has inhibitory effects on benzo[a]pyrene-induced mutageni-
city and clastogenicity (10). IH-901 exerts an anti-metastatic
activity partly through inhibition of tumor invasion (11).
It also has anti-platelet and anti-angiogenic activities (12),
and causes suppression of primary tumor growth in a
spontaneous metastasis model (13). Moreover, IH-901 has
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the ability to induce apoptosis in several tumor cell lines
(14--18).
Tumor promotion often accompanies an elevated ornithine
decarboxylase (ODC) activity or its expression, generation of
free radicals and reactive oxygen species, depletion of cellular
antioxidant capacity and acute inflammation characterized by
skin edema and hyperplasia, and induction of cyclooxygenase-2
(COX-2) (19). As part of our research program to evaluate the
chemopreventive potential of IH-901, we have examined the
antitumor promotional activity of IH-901 by determining its
effects on TPA-induced papillomagenesis as well as expres-
sion of COX-2 and ODC. To further elucidate the molecular
mechanisms underlying the antitumor-promoting activity of
IH-901, its effects on TPA-induced activation of NF-kB and
the upstream signaling kinases were also explored.
Materials and methods
Chemicals
IH-901 was prepared by large-scale incubation of protopanaxadiol-type
ginseng saponins (5 g) with human intestinal bacteria subcultured in general
anaerobic medium at 37C for 2 days. After incubation, the cultured media
were extracted with n-BuOH, washed with water and saline successively, and
centrifuged. The supernatant was concentrated in vacuo and subjected to
column chromatography over Kieselgel 60 with CHCl3-MeOH-H2O
(70:30:5T, v/v) and LiChroprep RP-8 using 80--85%MeOH as eluent to afford
IH-901 (320 mg), which was characterized by mass spectroscopy and 1H- and
13C-nuclear magnetic resonance spectrometry as reported previously (4). The
purity of the compound as assessed by HPLC was498%. TPA was obtained
from Alexis Biochemicals (San Diego, CA). All other chemicals used were in
the purest form available commercially.
Animals
Female ICR mice (6--7 weeks of age) were supplied from the Dae-Han
Bio-link Experimental Animal Center (Daejeon, Korea). The animals were
housed in climate-controlled quarters (24  1C at 50% humidity) with a 12-h
light/12-h dark cycle. The dorsal side of the skin was shaved using an electric
clipper, and only those animals in the resting phase of the hair cycle were used
in all experiments.
Measurement of mouse ear edema
Groups of four to six female ICR mice were treated on their right ear with
IH-901 in 20 ml 10% H2O in acetone or the vehicle alone 30 min prior to
application of 5 nmol TPA. The mice were killed 5 h later, and ear punches
were prepared. The increased weight of the ear punch from TPA-treated mice
was a measure of inflammation.
Measurement of PGE2
The female ICR mice (5 mice/group) were topically treated on their shaven
backs with indicated doses of IH-901 30 min prior to TPA (10 nmol) applica-
tion and were killed by cervical dislocation 5 h later. IH-901 was dissolved in
200 ml 10% H2O in acetone, and TPA was dissolved in 200 ml of acetone and
applied to the dorsal shaven area. The pulverized skin was homogenized with
ice-cold ethanol and centrifuged for 10 min at 3000 g. Supernatant was diluted
to 15% with respect to ethanol by adding 0.1 M sodium formate, and pelleted
protein was dissolved in 8 M urea. The diluted supernatant was applied to a
pre-activated AmprepTM C-18 reverse phase cartridge (Amersham Pharmacia
Biotech, Buckinghamshire, UK), and eicosanoids were released by ethyl-
acetate containing 1% methanol. The extract was evaporated to dryness
under a gentle stream of nitrogen and re-suspended in an enzyme immunoassay
buffer. The amounts of PGE2 were measured by using the PGE2 enzyme-
immunoassay (EIA) kit (Amersham Pharmacia Biotech Inc.) according to the
manufacturer’s protocol. The quantity of dissolved protein was determined by
the BCA method.
Western blot analysis
For isolation of protein from mouse skin, the dorsal skin was excised, and after
the fat was removed on ice, the remaining skin tissues were immediately
placed in liquid nitrogen and pulverized in mortar. The pulverized skin was
homogenized on ice for 20 s with a Polytron tissue homogenizer and lysed in
2 ml ice-cold lysis buffer [150 mMNaCl, 0.5% Triton X-100, 50 mMTris--HCl
(pH 7.4), 20 mM EGTA, 1 mM dithiothreitol (DTT), 1 mM Na3VO4, protease
inhibitor cocktail tablet (Roche Molecular Biochemicals, Mannheim,
Germany)] for 10 min. Lysates were centrifuged at 12 000 g for 20 min, and
supernatant containing 30 mg protein was boiled in sodium dodecyl sulfate
(SDS) sample loading buffer for 10 min before electrophoresis on 12%
SDS--polyacrylamide gel. After electrophoresis for 2 h, proteins in SDS--
polyacrylamide gel were transferred to PVDF membrane (Gelman Laboratory,
Ann Arbor, MI), and the blots were blocked with 5% non-fat dry milk-PBST
buffer [phosphate-buffered saline (PBS) containing 0.1% Tween-20] for
60 min at room temperature. The membranes were incubated for 2 h at room
temperature with 1:1000 dilution of the following antibodies: COX-2 and
COX-1 (Cayman Chemical, Ann Arbor, MI), p65 (Zymed Laboratories,
San Francisco, CA), ERK (Santa Cruz Biotechnology, Santa Cruz, CA), Akt
and phospho-Akt polyclonal antibodies (Cell Signaling Technology, Beverly,
MA), phospho-ERK (Santa Cruz Biotechnology) and ODC (NeoMarkers,
Fremont, CA) monoclonal antibodies. Equal lane loading was assessed using
actin (Sigma-Aldrich, St Louis, MO). The blots were rinsed three times with
PBST buffer for 5 min each. Washed blots were incubated with 1:5000 dilution
of the horseradish peroxide-conjugated secondary antibody (Zymed Labor-
atories, San Francisco, CA) and then washed again three times with PBST
buffer. The transferred proteins were visualized with an enhanced chemilumi-
nescence detection kit (Amersham Pharmacia Biotech, Inc.).
Preparation of nuclear extracts
Nuclear extract was prepared from mouse skin as described previously (20).
Briefly, scraped dorsal skin of mice was homogenized in 1 ml of ice-cold
hypotonic buffer A [10mMHEPES (pH 7.8), 10 mMKCl, 2 mMMgCl2, 1 mM
DTT, 0.1 mM EDTA, 0.1 mM phenylmethylsulfonylfluoride (PMSF)]. After a
15-min incubation on ice, the nucleoprotein complexes were lysed with 125 ml
of 10% Nonidet P-40 (NP-40) solution, followed by centrifugation for 2 min at
14 800 g. The nuclei were washed once with 400 ml of buffer A plus 25 ml of
10% NP-40, centrifuged, re-suspended in 150 ml of buffer C [50 mM HEPES
(pH 7.8), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.1 mM
PMSF and 10% glycerol], and centrifuged for 5 min at 14 800 g. The super-
natant containing nuclear proteins was collected and stored at 70C after
determination of protein concentrations.
Fig. 1. Metabolic formation of IH-901. IH-901 is formed from
protopanaxadiol-type ginsenosides, especially ginsenoside-Rb1, by
P.oris in the intestine after oral administration of ginseng.
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Electrophoretic mobility shift assay (EMSA)
EMSA was performed using a DNA--protein biding detection kit (Gibco BRL,
Grand Island, NY) according to the manufacturer’s protocol. Briefly, the
NF-kB oligonucleotide probe (50-AGT TGA GGG GAC TTT CCC AGG
C-30) was labeled with [g-32P]ATP by T4 polynucleotide kinase and purified
on a Nick column (Amersham Pharmacia Biotech, Inc.). The binding reaction
was carried out in a total volume of 25ml containing 10 mMTris--HCl (pH 7.5),
100 mM NaCl, 1 mM DTT, 1 mM EDTA, 4% glycerol, 0.1 mg/ml sonicated
salmon sperm DNA, 10 mg of nuclear extracts and 100 000 c.p.m. of the
labeled probe. After a 50-min incubation at room temperature, 2 ml of 0.1%
bromophenol blue was added, and samples were electrophoresed through a 6%
non-denaturating polyacrylamide gel at 150 V in a cold room for 2 h. Finally,
the gel was dried and exposed to the X-ray film. EMSA was performed with
nuclear extracts from at least three different sets of mouse skin, and the
intensity of NF-kB DNA binding was quantified by densitometry.
ODC assay
The female ICR mice were topically treated on their shaven backs with
indicated doses of IH-901 30 min before 10 nmol TPA treatment and were
killed by cervical dislocation 5 h later. The epidermis was separated by brief
heating (55C for 20 s). The epidermal preparation was homogenized in ice-
cold sodium phosphate buffer (50 mM; pH 7.8) containing 0.1 mM pyridoxal
phosphate and 0.1 mM EDTA, and centrifuged at 12 000 g for 20 min. The
ODC activity of the soluble epidermal extracts was determined by measuring
the release of 14CO2 from DL-[1-
14C]ornithine hydrochloride. 100 ml of super-
natant was incubated in a final volume of 40 mM sodium phosphate buffer
(pH 7.8) containing 8 mM DTT, 0.64 mM pyridoxal phosphate and 0.8 mM
EDTA with 2 mM DL-[1-14C]ornithine hydrochloride (sp. act., 2.5 mCi/mmol;
Amersham Pharmacia Biotech) as a substrate at 37C for 1 h. The released
14CO2 was captured in filter paper wet in Solvable
TM (Du Pont/NEN Research
Products, Boston, MA). The amount of radioactivity [14C] was measured by
liquid scintillation counting. The protein content was determined by the BCA
method. Data are expressed as the means  SD obtained from 4 to 5 mice/
group. Significantly different from the TPA alone group (P5 0.005).
Two-stage mouse skin carcinogenesis
Groups of 25--30 mice were treated on their shaven backs with a single topical
application of DMBA (0.2 mmol) in 0.2 ml acetone or the solvent alone. One
week after initiation, 15 nmol of TPA in acetone was topically applied twice
weekly until termination of the experiment at week 19. Each dose of IH-901
dissolved in 0.2 ml 10% H2O in acetone was topically applied 30 min before
TPA treatment. Beginning 1 week following the promotion, animals were
checked on a weekly basis for the presence of papillomas of at least 1 mm in
diameter. The results were expressed as the percentage of tumor-bearing mice
(incidence) and the average number of tumors per mouse (multiplicity).
Statistical analysis
Data are expressed as means  SD. Statistical significance of changes was
determined by the Student’s t-test. Differences resulting in P values 50.05
were considered to be statistically significant.
Results
Inhibitory effect of IH-901 on TPA-induced mouse ear edema
Since tumor promotion is closely related to inflammation, the
anti-inflammatory effect of IH-901 was initially examined.
Edema is a typical marker of inflammation. A single topical
application of TPA (5 nmol) alone onto the right ears of the
mice induced edema. When 0.1, 0.3 and 1 mmol of IH-901 was
treated topically 30 min before TPA application, ear edema
was suppressed by 17, 57 and 71%, respectively (Figure 2A).
IH-901 alone did not induce ear edema.
Inhibitory effects of IH-901 on TPA-induced COX-2 expression
and PGE2 production in mouse skin
We have shown previously that TPA, a prototypic tumor pro-
moter and a mitogen, stimulates COX-2 expression and PGE2
production in mouse skin (21,22). As illustrated in Figure 2B,
IH-901 pre-treatment resulted in marked inhibition of COX-2
expression in TPA-treated mouse skin without altering the
COX-1 level. In addition, topical application of the dorsal
skin of female ICR mice with 1 mmol IH-901 significantly
reduced the TPA-induced PGE2 synthesis (Figure 2C).
IH-901 alone did not affect the constitutive production of PGE2.
Inhibitory effect of IH-901 on TPA-induced NF-kB DNA
binding
Because NF-kB is known to play a critical role in regulating
the expression of COX-2, we have determined whether IH-901
Fig. 2. Effects of IH-901 on TPA-induced mouse ear edema, COX-2
expression and PGE2 production in mouse skin. (A) Female ICR mice were
treated on the right ear with IH-901 (0.1, 0.3 or 1 mmol) or vehicle alone
30 min before topical application of TPA (5 nmol) as described in the
Materials andMethods. Data are expressed as the means SD obtained from
4 to 6 mice/group. Significantly different from the TPA alone group
(P5 0.005). (B) Female ICRmice were treated topically with 0.2 ml of 10%
water in acetone or IH-901 (1, 3 or 10 mmol) in the same volume of vehicle
30 min prior to 10 nmol TPA, and animals were killed 4 h after the TPA
treatment. Protein was analyzed for COX-2 by immunoblotting. The
immunoblot is representative of three independent experiments. (C) Female
ICR mice were treated topically with IH-901 (1 mmol) or vehicle alone
30 min prior to 10 nmol TPA, and animals were killed 5 h after the TPA
treatment for PGE2 analysis. Data are expressed as the means SD obtained
from 5 mice/group. Significantly different from the group treated with TPA
alone (P5 0.005).
Antitumor promotional effect of IH-901 in mouse skin
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could suppress activation of this transcription factor in mouse
skin stimulated with TPA. Our previous studies demonstrated
a transient increase in epidermal NF-kB DNA binding
after application with 10 nmol TPA, which was abolished
by addition of the excess unlabeled probe (20). Effects of IH-
901 on NF-kB activation were examined with 1 mmol of the
compound topically applied 30 min prior to the TPA treatment.
Pre-treatment of IH-901 inhibited TPA-induced NF-kB activa-
tion in mouse skin (Figure 3A) while the compound alone did
not influence constitutive NF-kB activation (data not shown).
One of the most critical steps in NF-kB activation is the
dissociation of IkB, which is mediated through phosphoryla-
tion and subsequent proteolytic degradation of this inhibitory
subunit. To determine whether the inhibitory effect of IH-901
on NF-kB DNA binding was due to its suppression of IkBa
degradation through phosphorylation, the cytoplasmic levels
of phosphorylated IkBa were determined by western blot
analysis. Topical application of TPA led to substantial
increases in the phosphorylation of IkBa, which was signific-
antly repressed by IH-901 pre-treatment (Figure 3B). Like-
wise, degradation of IkBa was also blocked by IH-901. We
also measured the level of p65, the functionally active subunit
of NF-kB, in the nucleus. Upon TPA treatment, the nuclear
translocation of p65 increased, which was blocked by IH-901.
These results indicate that IH-901 inhibits TPA-induced
translocation of p65 to the nucleus by blocking IkBa degrada-
tion (Figure 3B).
Effect of IH-901 on TPA-induced activation of ERK
Mitogen-activated protein (MAP) kinases are known to regu-
late NF-kB activation by multiple mechanisms. Accumulating
evidence indicates that NF-kB activation is modulated by ERK
as well as p38 MAP kinase. We reported previously that
U0126, an ultrapotent inhibitor of MAP kinase kinase
(MEK)1/2, blocked the NF-kB DNA binding activity, whereas
the p38 MAP kinase inhibitor SB203580 failed to (22).
This result suggests that the activation of NF-kB occurs via
the ERK-dependent pathway in mouse skin. We examined
whether IH-901 could down-regulate ERK, thereby inactivat-
ing NF-kB and further suppressing the COX-2 induction. IH-
901 inhibited the phosphorylation of ERK1/2 in mouse skin
(Figure 4A). Under the same experimental conditions, the
level of the total form of ERK remained almost constant.
Effect of IH-901 on TPA-induced activation of Akt
Phosphoinositide 3-kinase (PI3-K) and its downstream target
Akt/protein kinase B are also known to regulate NF-kB activ-
ity (23,24). Akt serves as a stimulator of NF-kB signal path-
way by promoting IkB phosphorylation. Figure 4B showed
that pre-treatment of IH-901 suppressed TPA-induced phos-
phorylation of Akt in mouse skin. In order to investigate the
possible involvement of Akt in the signaling pathway mediat-
ing COX-2 induction, we examined the effect of the PI3-K
inhibitor LY294002 on the TPA-induced COX-2 expression.
We confirmed that LY294002 at 10 mmol suppressed the
activity of PI3-K (Figure 5A). However, LY294002 at a phar-
macologically effective dose failed to block the TPA-induced
COX-2 expression (Figure 5B). This finding suggests that the
PI3-K--Akt down-regulation by IH-901 may not contribute
substantially to its inhibition of TPA-induced COX-2 expres-
sion in mouse skin.
Fig. 3. Effect of IH-901 on TPA-induced NF-kB activation in mouse skin.
(A) Dorsal skin of mice was treated topically with acetone alone, 10 nmol
TPA alone or 1 mmol of IH-901 30 min before TPA treatment. Mice were
killed 1 h after the TPA treatment, and epidermal nuclear extracts were
prepared and incubated with the radiolabeled oligonucleotides containing the
NF-kB consensus sequence for analysis by the EMSA. EMSA was
performed with at least three different sets of mouse skin, and the intensity of
the NF-kB--DNA complex was quantified. (B) Cytoplasmic and nuclear
extracts from mouse skin treated 10 nmol TPA for 1 h, with and without
IH-901 (1 mmol) pre-treatment, were assayed for phosphorylated IkBa,
IkBa and p65 by western blot analysis.
Fig. 4. Effects of IH-901 on TPA-induced phosphorylation of ERK and
Akt in mouse skin. Female ICR mice were treated topically with acetone or
with 1, 3 or 10 mmol of IH-901 30 min prior to TPA. Mice were killed 4 h
after the TPA treatment; the phosphorylated form of ERK (A) or Akt (B) was
detected by immunoblotting using phospho-specific antibodies. Data are
representative of two independent experiments, which gave rise to a
similar trend.
J.-Y.Lee et al.
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Effects of IH-901 on TPA-induced ODC activity and
expression
ODC is a rate-limiting enzyme in the synthesis of polyamines
that play pivotal roles in cell growth and proliferation (25).
ODC is rapidly induced by many mitogenic stimuli including
TPA and has been hence regarded as a biochemical hallmark
of tumor promotion (26). As ODC expression peaked at ~4 h
following TPA (10 nmol) treatment (Figure 6A), the effect of
IH-901 on ODC was determined at this particular time point.
When applied topically onto shaven backs of mice 30 min
prior to TPA, IH-901 inhibited the epidermal ODC expression
in a dose-dependent manner (Figure 6B). Likewise, the TPA-
induced ODC activity was repressed by same doses of IH-901
(Figure 6C). IH-901 alone did not affect constitutive expres-
sion and activity of ODC.
Inhibitory effect of IH-901 on TPA-induced mouse skin tumor
promotion
To examine whether IH-901 has an antitumor-promoting
activity, the dorsal skin of mice was subjected to topical
application of IH-901 prior to each TPA in the entire promo-
tion stage. The first appearance of papillomas occurred
at the eighth week of promotion. The DMBA-TPA group
exhibited the 100% incidence of skin tumors with approxi-
mately 16 papillomas per mouse at 18th week. When IH-901 at
a dose of 0.5 or 2.5 mmol was applied topically onto the shaven
backs of mice 30 min prior to each TPA application,
the average number of papillomas per mouse was reduced by
47 and 63%, respectively (Figure 7A). However, IH-901
Fig. 5. Effects of LY294002 on Akt phosphorylation and COX-2 expression
in mouse skin. Female ICR mice were treated topically with acetone or
LY294002 (10 mmol) 30 min prior to 10 nmol TPA, and animals were killed
4 h after the TPA treatment. Protein was analyzed for phospho-Akt and
COX-2 by immunoblotting. Quantification of phospho-Akt and COX-2
expressions was normalized to total Akt or actin using a densitometer.
Significantly different from the group treated with TPA alone
(P5 0.01).
Fig. 6. Effects of IH-901 on TPA-induced ODC expression and activity in
mouse skin. (A) Dorsal skins of female ICR mice were treated topically with
acetone alone or with 10 nmol TPA in acetone for indicated time periods.
Protein extracts (30 mg) were loaded onto a 12% SDS--polyacrylamide gel,
electrophoresed, and subsequently transferred onto PVDF membrane.
Immunoblots were probed with a monoclonal ODC antibody. (B) Mice were
treated topically with acetone or with 1, 3 or 10 mmol of IH-901 30 min prior
to 10 nmol TPA. Mice were killed 4 h after the TPA treatment for the
measurement of ODC expression. (C) Female ICR mice were treated
topically with 1, 3 or 10 mmol of IH-901 30 min prior to the application of
10 nmol TPA. The animals were killed 5 h after the TPA treatment, and
epidermal ODC activity was measured. Data are expressed as the
means  SD obtained from 4 to 5 mice/group. Significantly different
from the TPA alone group (P5 0.005).
Antitumor promotional effect of IH-901 in mouse skin
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pre-treatment did not significantly lower the percentage
of tumor-bearing mice at the termination of the experiment
(Figure 7B).
Discussion
In recent years considerable effort has been made to develop
chemopreventive agents that could inhibit, retard or reverse
the multistage carcinogenesis (27). Tumor promotion is closely
linked to inflammation and oxidative stress (28,29), and it is
hence likely that compounds with strong anti-inflammatory
and anti-oxidative activities act as antitumor promoters as well.
Our previous studies have demonstrated the anti-inflamma-
tory effects of several ginsenosides (Rb1, Rc, Re, Rg1 and
Rg3) derived from P.ginseng (30). Topical application of
each of these ginsenosides significantly attenuated ear
edema induced by TPA. These ginsenosides also suppressed
the expression of COX-2 and activation of NF-kB in the TPA-
treated dorsal skin of mice (30). Of the ginsenosides tested,
Rg3 was found to be most effective in terms of inhibiting TPA-
induced ear edema, COX-2 expression and NF-kB activation.
IH-901 is the major metabolite formed by intestinal bacteria
from protopanaxadiol class ginseng saponins. It has been
demonstrated that the in vivo anti-metastatic effects of some
ginsenosides are mediated by this metabolite (11). IH-901 is
known to be non-toxic, to inhibit glucose uptake by tumor cells
(9), and to reverse multi-drug resistance in tumor cells (31).
Moreover, IH-901 possesses chemopreventive potential, as
evidenced by inhibition of genotoxicity and clastogenicity
induced by benzo[a]pyrene (10). As an initial approach to
evaluate the antitumor-promoting potential of IH-901, its
effect on tumor promoter-induced inflammation was initially
assessed by employing a mouse ear edema model. Topical
application of IH-901 resulted in marked attenuation of TPA-
induced inflammation in the mouse ear. In the subsequent
experiment, the antitumor promotional activity of IH-901
was confirmed in a two-stage mouse skin carcinogenesis.
There is a growing body of compelling evidence that tar-
geted inhibition of COX-2 expression or activity is valuable
for not only alleviating inflammation, but also in the therapeu-
tic prevention of cancer (32). Therefore, agents that interfere
with the intracellular signaling mechanisms governing the
transcription of COX-2 are considered to be potential chemo-
preventives. In our present study, topically applied IH-901
inhibited TPA-induced PGE2 production almost completely
at a dose that partially blocks COX-2 expression. This finding
suggests that the antitumor-promoting effects of IH-901 can
be attributed, in part, to inhibition of not only expression of
COX-2 but also its catalytic activity. It is interesting to note
that IH-901 barely affected the levels of the housekeeping
enzyme COX-1. Since targeted inhibition of COX-2 without
affecting the COX-1 expression is recognized as one of the
most promising strategies for chemoprevention, IH-901 with
selective COX-2 inhibitory activity has a therapeutic potential.
It would be worthwhile comparing the anti-inflammatory as
well as chemopreventive effects of IH-901 and its parental
ginsenoside(s).
Control of cox-2 induction involves a complex array of
regulatory factors including NF-kB (33,34). Pre-treatment of
the dorsal skin of mice with IH-901 inhibited the NF-kB DNA
binding by blocking of p65 nuclear translocation and IkBa
degradation. According to our previous study, topical applica-
tion of the NF-kB inhibitor pyrrolidine dithiocarbamate
resulted in the suppression of TPA-induced COX-2 expression
in mouse skin (35). The data also support the notion that the
naturally occurring anti-inflammatory agent IH-901 inhibits
TPA-induced COX-2 expression in mouse skin, possibly by
blocking NF-kB activation. Another transcription factor that
plays an important role in controlling cox-2 gene is activator
protein-1 (AP-1). A role of AP-1 in COX-2 induction has been
demonstrated in various cell lines (36--38). Topical application
of IH-901 suppressed TPA-stimulated AP-1 activation in
mouse skin (data not shown). Therefore, it is plausible that
IH-901 inhibits COX-2 expression through not only inactiva-
tion of NF-kB but also other transcription factors including
AP-1 in mouse skin.
The molecular signaling mechanisms involved in the induc-
tion of COX-2 as well as activation of transcription factors
Fig. 7. Antitumor-promoting effects of IH-901 on mouse skin
carcinogenesis. Female ICRmice were treated with 0.5 (~) or 2.5 (!) mmol
of IH-901 in 10% H2O in acetone or the solvent alone (*) 30 min prior to
each topical application of TPA (15 nmol) after initiation with DMBA
(0.2 mmol). Control animals were treated with acetone in lieu of TPA (*).
The asterisk indicates that the multiplicity of tumors is significantly lower
than that observed in the DMBA-TPA group (P5 0.01).
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including NF-kB in response to various external stimuli have
not been fully clarified. One of the most extensively investi-
gated intracellular signaling cascades involved in pro-
inflammatory responses is the MAP kinase pathway. MAP
kinases regulate NF-kB activation via multiple mechanisms.
Our previous studies have demonstrated that the ultrapotent
MEK1/2 inhibitor U0126 abolished the NF-kB binding activ-
ity and COX-2 expression in TPA-treated mouse skin (22),
which supports the notion that ERK may play an important
role in the signaling pathway mediating TPA-induced COX-2
expression and NF-kB activation in mouse skin. Therefore, we
examined whether IH-901 could also block ERK activation by
inhibiting phosphorylation of this MAP kinase. Topical appli-
cation of IH-901 suppressed TPA-induced ERK phosphoryla-
tion in a dose-dependent manner. These results may provide
the molecular basis for the inhibitory effect of IH-901 on
NF-kB activation in TPA-treated mouse skin in vivo.
The serine/threonine kinase Akt is activated by numerous
growth factors and many other stimuli (39). Activated Akt
functions to promote cell survival by inhibiting apoptosis
through its ability to phosphorylate and inactivate down-
stream targets (40). Recent reports have shown that Akt
regulated COX-2 gene and protein expressions in phospho-
Akt expressing endometrial cancer cells and inhibition of
PI3-K with wortmannin and LY294002 blocked IkB phos-
phorylation, reduced NF-kB nuclear activity and COX-2
expression and induced apoptosis (41). In our current work,
Akt was activated via phosphorylation in mouse skin
in response to TPA treatment and inhibited by IH-901 pre-
treatment. However, LY294002 had no effect on COX-2
expression despite its ability to inhibit PI3-K activity. These
findings suggest that the PI3K--Akt signaling pathway may not
be a major target of IH-901 in its suppression of TPA-induced
COX-2 expression in mouse skin. The utilization of geneti-
cally tractable mouse models, in which PI3K or Akt is func-
tionally knocked out, would better test the validity of such
conclusion.
ODC, a rate-limiting enzyme catalyzing biosynthesis of
polyamines, is a biochemical hallmark of tumor promotion
(42). Therefore, suppression of ODC induction during the
carcinogenic process has been recognized as an important
and commonly acceptable approach for the effective inhibition
of tumor promotion (43). In the present study, TPA-induced
ODC expression as well as enzyme activity was inhibited by
Fig. 8. Schematic representation of the possible targets of IH-901 and selected ginsenosides in the signal transduction pathway.
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IH-901 pre-treatment in a dose-dependent manner. The mole-
cular mechanisms underlying suppression of ODC expression
and catalytic activity by IH-901 remains to be clarified. ODC
induction is subjected to a complex array of cell-specific
regulatory mechanisms that govern transcription, mRNA
stability, translation and enzyme degradation (25). Kubota
et al. (44) found that ODC over-expressing cells showed
enhanced ERK activity, compared with the control transfec-
tant. According to this study, the enhanced ERK activity in
ODC over-expressing transfectant appears to be responsible
for the neoplastic transformation and cell invasion observed in
this genetically engineered cell line. Other investigators have
reported that ODC over-expression stimulates MAP kinase
expression and anchorage-independent growth in human
breast cancer cells (45). MAP kinases have also been reported
to be involved in the expression of ODC in leukemia cells (46)
and in human ECV304 cells (47). Based on these findings, the
persistent activation of the MAP kinase pathway, which is
thought to have an important role in oncogenesis, is likely to
cause elevated ODC expression. Pharmacologic inhibition of
ERK by specific MEK1/2 blockers, such as U0126 and
PD98059, prevented the induction of ODC (47), lending
further support to the above supposition. Therefore, the induc-
tion of ODC would be down-stream of ERK activation. The
association of another kinase Akt with ODC was also demon-
strated in mouse leukemia (48). Additional studies will be
necessary to clarify that the inhibitory effect of IH-901 on
the TPA-induced ODC expression could be mediated through
down-regulation of the ERK and/or Akt pathway.
The antitumor-promoting effect of IH-901 on mouse skin
carcinogenesis was found to be more prominent in terms of
reducing the multiplicity while the tumor incidence was inhib-
ited to a lesser extent. This is not surprising if one considers
the proapoptotic and anti-angiogenic properties of IH-901
(14--18). By eliminating the damaged cells in an early stage
and by blocking the tumor-induced ‘neovascularization’,
IH-901 is likely to prevent the tumor cells to spread out.
In conclusion, the present study demonstrates that IH-901
inhibits induction of COX-2 and ODC in TPA-treated mouse
skin in vivo. Since improper and abnormal over-expression of
COX-2 and ODC is implicated in the pathogenesis of various
types of cancers, assessment of the effects of IH-901 on the
expression of these two enzymes may be a useful surrogate
biomarker for the evaluation of its activity in chemoprevention
trials. Our findings that IH-901 inhibits TPA-induced COX-2
expression by blocking the ERK and NF-kB signaling cas-
cades may provide a molecular basis for suppression of mouse
skin tumor promotion as well as inflammation elicited by this
chemopreventive phytochemical (Figure 8).
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